Biogen Reports Long-Term PRIME Extension Data for Aduhelm in Early Alzheimer's Disease

Biogen today presented long-term extension data from the PRIME trial evaluating Aduhelm (aducanumab) in patients with early Alzheimer's disease. The data showed that Aduhelm maintained significant amyloid plaque reduction over extended treatment, with patients who continued treatment showing sustained benefits. The long-term safety profile was consistent with previous observations.